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Abstract 
There are many proteomic applications that require large collections of purified protein, 
but parallel production of large numbers of different protein remains a very challenging task.  To 
help meet the needs of the scientific community, we have developed a human protein production 
pipeline.  Using high-throughput methods, we transferred the genes of 31 full-length proteins 
into three expression vectors, and expressed the collection as N-terminal HaloTag fusion proteins 
in E. coli and two commercial cell-free systems, wheat germ extract and HeLa cell extract.  
Expression was assessed by labeling the fusion proteins specifically and covalently with a 
fluorescent HaloTag ligand and detecting its fluorescence on a LabChip® GX microfluidic 
capillary gel electrophoresis instrument.  This automated, high-throughput assay provided both 
qualitative and quantitative assessment of recombinant protein.  E. coli was only capable of 
expressing 20% of the test collection in the supernatant fraction with ≥20 μg yields, whereas 
cell-free systems had ≥83% success rates.  We purified expressed proteins using an automated 
HaloTag purification method.  We purified 20%, 33%, and 42% of the test collection from E. 
coli, wheat germ extract, and HeLa cell extract, respectively, with yields ≥1 μg and ≥90% purity.  
Based on these observations, we have developed a triage strategy for producing full-length 
human proteins in these three expression systems. 
Keywords 
Human protein, cell-free protein expression, in vitro transcription translation, Escherichia coli, 
E. coli expression, wheat germ extract, HeLa cell extract, microfluidic capillary gel 
electrophoresis, high throughput, protein expression, protein purification, high throughput 
expression analysis, full-length protein, HaloTag, SIFT  
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Abbreviations and symbols 
High Throughput (HT); Wheat Germ Extract (WGE); HeLa Cell Extract (HCE); Cell Free (CF); 
Continuous Exchange Cell Free (CECF); Protein Of Interest (POI); Microfluidic Capillary Gel 
Electrophoresis (MCGE); Tobacco Etch Virus (TEV); Selective Irreversible Fluorescence 
Targeting (SIFT) 
Significance Statement 
Proteomics endeavors to understand the function and relationships of all genetically encoded 
proteins, yet only a small percentage of the human proteome has been empirically isolated and 
characterized.  Considerable effort has been made to address the challenges of proteomic protein 
production using E. coli as an expression host.  We have developed a pipeline for producing 
human proteins that incorporates two eukaryotic cell-free expression systems which can produce 
a high percentage of full length human proteins.  
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Introduction 
The broad goals of proteomics include understanding the composition, structure, and 
function of all proteins in biological systems, as well as how the various components collectively 
contribute to phenotype.  The technologies employed to meet these goals have advanced 
considerably over the past decade, especially in regard to the throughput capability of sample 
preparation, assaying, and data analysis. However, high-throughput (HT) protein production 
continues to be a bottleneck despite the need for purified proteins in many aspects of protein 
characterization, such as structure determination
1
, enzymatic activity analysis
2-4
, and protein 
identification and quantification
5
.  Purified proteins are also needed for all current methods 
performing affinity reagents development.  Unfortunately, the high cost and limited availability 
of purified proteins have resulted in a lack of highly-specific and high-quality affinity reagents 
targeting the majority of human proteins
6
.  Large efforts such as the Protein Capture Reagent 
Program at the NIH (http://commonfund.nih.gov/proteincapture) aim to address this widespread 
need.  A number of the technologies employed by that program require starting with purified 
antigen in the range of several to tens of micrograms.  However, even with such low quantity 
requirements, the lack of availability and high cost of pure antigens remains a major roadblock 
towards the goals of producing affinity reagents for the proteome, novel technology development 
and scientific knowledge advancement. 
Escherichia coli (E. coli) has established itself as the predominant organism for protein 
production because of the low cost, easy manipulation, and the extensive knowledge 
accumulated over the past thirty years
7,8
.  We have previously reported on the in vivo and in vitro 
high throughput production of human proteins in E. coli
9,10
.  While excellent for some proteins, 
E. coli is poorly suited for producing multi-domain full-length eukaryotic proteins that are 
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generally larger than 50 kDa.  The problems are often related to poor solubility and ensuing 
toxicity when over expressed in bacteria despite extensive effort devoted to circumvent these 
challenges
8,10-14
.  As full-length proteins are not a requirement for structural genomics, many 
protein production centers create many different constructs for each protein of interest (POI).  
Variants are generated by truncating unstructured regions of protein, parsing domains, using 
multiple fusion tags and purification strategies, employing vectors with varied promoters, and 
testing different expression and induction conditions, etc., to increase the success rate of 
expression and purification
7,11,12,14-17
.   Processing multitudes of constructs requires additional 
time, labor, costs, and bioinformatics support.  When multiplied by the scale of the proteome, 
this approach becomes costly. 
The use of insect or mammalian cells for in vivo recombinant protein production has 
alleviated some key limitations associated with prokaryotic expression systems.  Eukaryotic 
expression systems possess the ability to translate and support correct folding of large, multi-
domain eukaryotic proteins, and to perform eukaryotic posttranslational modifications (PTMs) 
that are essential for function
10,18-21
.  However, in vivo eukaryotic expression systems are limited 
by high cost and labor intensity, difficulty in cell lysis, toxicity, batch variations, and difficulty to 
automate for HT production
22-24
. 
Significant advances in recent years have been made in the development of commercial 
eukaryotic cell-free (CF) expression systems.  Although historically the yields of protein were 
low enough to require isotopic labeling
25
, the efficiency of eukaryotic CF expression systems has 
improved dramatically, substantially lowering the cost per unit of protein produced.  Two new 
systems in particular, the Wheat Germ Extract (WGE)-based WEPRO 7240 series (CellFree 
Science), and HeLa Cell Extract (HCE) 1-Step Human High-Yield IVT line (Thermo Scientific), 
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have both been reported to express substantially more protein than their predecessors
19,26
.  A key 
advantage of CF systems over in vivo eukaryotic expression is that CF expression protocols 
better facilitate automation, and lack many of the requisite steps of in vivo methods, including 
the selection of high expression clones, cell culture, and cell lysis, that are associated with in vivo 
work.  Moreover, there is minimal batch-to-batch variation, and protein toxicity is not a concern.  
These systems have been shown to support some PTMs, including phosphorylation, but most 
likely have limited capacity to perform other PTMs, such as glycosylation and disulfide bond 
formation, which makes them less suitable for expressing secreted and membrane proteins. 
Very few studies have investigated the suitability of WGE for HT protein 
production
19,27,28
, and fewer still have tested HCE systems
5
.  There is a great disparity between 
the adoption of CF systems and the use of E. coli for protein expression.  In contrast with E. coli, 
the expression host for 88% of structure determined proteins in the Protein Data Bank (PDB), 
less than 0.5% of protein structures were determined from proteins generated by CF 
expression
20
.  Previously reported E. coli protein production pipelines have highly variable 
success rates, and are largely influenced by each study’s target selection criteria and the 
application-dependent standard of success; collections that are biased towards smaller proteins 
with predicted similarity to structurally determined proteins, or have been domain parsed or 
truncated, tend to have higher success rates.  Reported E. coli expression success rates range 
from 20-80%
9-14,16,28
.  In some of these works, protein collections that were reported to have low 
success rates in E. coli had much higher success rates of about 65-95% in WGE
10,16,28
.  Selection 
bias for proteins that are likely to express and purify can increase the success rate significantly, 
but results in many proteins that are untried and uncharacterized.  HT methods that succeed in 
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expressing and purifying a high percentage of a large, diverse collection of proteins are highly 
desired. 
Automation of the protein production process, from cloning to assaying purified protein, 
is essential for HT capacity.  Productive pipelines automate the most labor intensive steps, which 
have traditionally been culturing E. coli, purifying proteins, and characterizing expressed and 
purified recombinant protein.  The use of liquid handling robots has become routine at protein 
production centers to address these needs.  Expression and purification are performed in 96-well 
deepwell block format that conforms to robotic liquid handler operation.  HT protein analysis 
that provides both qualitative and quantitative data has been facilitated with the adoption of 
microfluidic capillary gel electrophoresis (MCGE).  These microfluidic characterization 
methods, however, analyze total, nonspecific protein.  The use of microfluidic systems to 
evaluate recombinant proteins specifically has not been widely incorporated into protein 
production center pipelines.  Developing protein production pipelines will benefit from the 
ability to specifically detect recombinant protein with a HT assay. 
The goal for this study was to establish a pipeline that supports HT full-length human 
protein production with greater than 90% purity at the scale of tens of micrograms. We compared 
the performance among two eukaryotic CF expression systems, HCE and WGE, and the 
conventional E. coli expression strategy.  We tested 31 full-length proteins ranging in size from 
10 to 120 kDa in expression vectors that utilized Gateway™ technology.  We developed a 
selective binding reagent and an associated method that allows the specific fluorescent 
evaluation of recombinant protein in a complex protein mixture using MCGE.  Using HaloTag as 
a fusion partner
29,30
, proteins-of-interest were purified in all three expression systems on an 
automated platform.  We successfully purified 45% of these full-length proteins.  We 
Developing a human protein production pipeline 9 Tuesday, December 16, 2014 
 
demonstrated that both eukaryotic CF systems were far more capable of generating larger 
proteins than E. coli. 
Results 
HaloTag expression vector construction.  We decided to use a solubility enhancing fusion tag, 
HaloTag, for our development.  Solubility enhancing fusion tags have been reported to improve 
success rates of E. coli protein production
9,11
, but the benefits of these tags for CF expression is 
less understood.  HaloTag binds covalently to a chloroalkane substrate that can be immobilized 
on beads for purification or linked to various functional groups for downstream assays
29,30
.  We 
found that the solubility of several proteins expressed as HaloTag fusion proteins was 
comparable to other commonly used affinity tags, like glutathione S-transferase (GST) and 
maltose binding protein (MBP). 
Three expression vectors were constructed to support protein expression and purification 
in the three systems of interest, pCPD_nHalo for E. coli expression, pJSP6_nHalo for WGE, and 
pJFT7_nHalo for HCE (Supporting Information Fig. S1).  These plasmids were adapted from 
established expression vectors pMCSG32, pEU_HSBC, and pANT7_cGST for E. coli, WGE, 
and HCE, respectively, to express POIs with an N-terminal HaloTag and Tobacco Etch Virus 
(TEV) protease cleavage site.  The vectors we developed function as Gateway destination 
vectors, enabling the transfer of full-length human genes in frame through a one-step 
recombination reaction, and are compatible with tens of thousands of available open reading 
frame (ORF) constructs
31,32
. 
Protein selection.  We selected 31 full-length proteins (30 human and 1 mouse) listed in Table 
S1 to evaluate the expression capabilities of the three expression systems.  The proteins were 
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chosen if they were (1) involved in cancer pathways
33
, (2) their full-length cDNA was available 
in our plasmid repository of ~10,000 human genes in a Gateway donor vector
32
, and (3) were not 
membrane proteins. In addition, several of the selected proteins had previously been produced by 
a Protein Structure Initiative (PSI) center (http://www.nesg.org/).  The test collection of 31 
proteins ranges in size from ~10-120 kDa, and includes 7 kinases and 4 transcription factors.  
Otherwise, no special selection method was used to create this collection. 
Cell Free Expression Systems.  The WGE and HCE CF systems differ in several aspects.  The 
WGE system performs transcription and translation in two consecutive steps, whereas HCE is a 
coupled transcription and translation system.  The coupling of transcription and translation 
enables the use of cDNA as a direct input for protein expression, which is essential for some 
proteomic applications
26,34
.  The yield of both systems can be increased by implementing a 
continuous-exchange cell-free (CECF) expression format, in which the translation reaction 
occurs in a semi-permeable chamber that is supplied with translation reactants and allows 
byproducts to diffuse away.  In addition, WGE can utilize a bilayer format that accomplishes a 
similar effect without the need of a dialysis membrane, making it more amenable to automation.  
In this format, the combined volume of the reaction mixture and dialysis buffer is collected for 
downstream applications such as purification.  As illustrated in Fig. S2, we used the dialysis 
format for HCE expression and the bilayer format for WGE expression. 
HT HaloTag Protein Expression Analysis.  In developing our HT platform, we sought a rapid 
and simple method to assess production of our recombinant proteins, which is commonly 
achieved through the use of low-throughput slab gel SDS-PAGE.  To observe all proteins, gels 
are often stained with Coomassie brilliant blue.  Visualizing the specific recombinant protein 
typically requires the complex multistage process of immunoblotting, including transferring the 
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proteins to membranes and probing with specific antibodies.  When production shifts to HT, the 
cumbersome nature of slab gels must give way to automated MCGE systems, such as the 
LabChip platform.  To measure all proteins, these microfluidic systems mix protein samples with 
an amine-reactive fluorescent dye that labels proteins non-specifically, and detect proteins with 
laser-induced fluorescence at the end of the separation channel.  This provides an analysis akin to 
Coomassie-stained SDS-PAGE slab gels.  Although LabChip instruments are not typically used 
to specifically visualize recombinant proteins in complex samples, there are automated 
immunoblot MCGE systems that perform this function
35
; however, these systems are dedicated 
solely to immuno-MCGE protocols and lack a total protein detection mode, depend on antibody 
performance, and have lower throughput than LabChip instruments. 
To address this shortfall, we developed a HT HaloTag protein detection method without 
the need for blotting or antibodies.  HaloTag fusion proteins in a complex protein mixture can be 
specifically labeled with a fluorescently conjugated HaloTag ligand that binds covalently to the 
HaloTag fusion.  The protein samples can then be denatured, separated by SDS-PAGE, and the 
in-gel fluorescent signal measured with a fluorescent imager
29
.  To develop a method for a 
microfluidics platform, we combined the HaloTag ligand with Alexa660 and used this to label 
our recombinant proteins.  This was tested on the LabChip GX instrument, which detects the 
Alexa660 fluorophore, and we observed that HaloTag fusion proteins can be assessed 
specifically and in parallel with the standard measurements of total protein.  We refer to this 
approach as Selective Irreversible Fluorescence Targeting (SIFT).  Fig. 1 compares total protein 
and HaloTag-specific signals on a slab gel with the equivalent MCGE assays on a LabChip GX 
system. 
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HT Protein Expression Protocol Development.  When working with a varied collection of 
proteins, protein-dependent effects, especially toxicity in E. coli, can cause variation in pre-
induction growth rate and expression yield.  Optimization can be performed individually for each 
protein, but this is a labor intensive approach and unsuitable for HT protein production.  
Accordingly, the imperative of HT expression is to express as many proteins as possible using 
the smallest number of protocols.  Many parameters were tested to optimize overall protein 
expression of the test collection, including evaluating multiple E. coli expression strains, 
induction strategies, and growth media.  IPTG-induced minimal media and lower expression 
temperatures were found to provide the most consistent induction strategy and resulted with the 
highest fraction of tested proteins in the soluble fraction compared with either nutrient rich media 
or auto-inducing media.  For CF systems, multiple parameters were assessed, including CF 
expression formats, transcription template concentration, expression time, and temperature.  
Manufacturer recommended conditions were found to be optimal for most of these factors.  The 
bilayer format for WGE and dialysis format for HCE both provided the most efficient expression 
configurations for most proteins, and with these formats, overnight expression gave higher yields 
than shorter incubations.  Using optimal conditions described in the Methods section, the test 
collection was expressed in the three systems. 
Expression system comparison.  Expression of the full-length protein collection in all three 
systems was assessed using the SIFT assay, and the virtual gels shown in Fig. 2 specifically 
show the recombinant protein in all supernatant fractions.  A comparison of slab gel and 
LabChip virtual gel for the HCE collection is shown in Fig. S3.  LabChip-SIFT protein 
quantification was found to be comparable to slab-gel based quantification (Fig. S4).  Nearly all 
proteins migrate in the LabChip assay as they do in a slab gel.  Several proteins were expressed 
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at high levels in all three expression systems; however, these proteins tend to be the smaller 
members of the collection, due primarily to the low expression success rate of E. coli for larger 
proteins.  Many proteins did express in E. coli, but approximately half of these were insoluble: 
the total fractions of these samples show fluorescently labeled HaloTag proteins, but the signal is 
absent in the supernatant fraction.  This indicates that these insoluble fusion proteins contain a 
functional HaloTag.  With the exception of MYOT, which had low solubility in all three 
systems, every other protein that expressed in a CF system was soluble.  There is a clear trend 
that E. coli does not efficiently produce larger proteins (>80 kDa), whereas WGE and HCE 
systems express these better.  As can be seen in the heat map of recombinant fusion protein 
quantification, expression yield was more variable in E. coli and HCE, while WGE expressed the 
collection at more homogenous levels.  Average expression yields are shown in Table 1. 
Degradation of full-length protein into a stable HaloTag end product was observed in 
both E. coli and HCE expression systems.  This proteolysis has been observed in similar studies 
with different fusion tags
9
.  This degradation, along with overall expression full-length protein 
yield, coincided with longer incubation times.  Notably, this degradation was minimal for bilayer 
WGE produced protein. 
Full-length Human Protein Purification with HaloTag.  Expression reactions were bound to 
magnetic HaloTag ligand resin. Using a liquid handling robot, the resin was washed to remove 
unbound proteins, and POIs were released by cleavage with a HaloTag fusion TEV protease that 
itself also bound to available ligand on the resin.  To optimize protein purification, numerous 
parameters were tested, including the amount of protease, resin-to-sample ratio, binding time, 
number of washes, cleavage time, resin equilibration buffers, and type of detergent.  In general, 
the HaloTag purification strategy was found to be robust, as yield and purity changed little with 
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respect to choice of buffer (HEPES, PBS, TBS), reducing reagent (DTT, TCEP), or detergent 
(IGEPAL, TWEEN).  Resin and protease quantity significantly impacted the yield of purified 
protein, and notably, excess resin decreased yield.  When the resin was washed less than five 
times after the binding step, overall protein purity was lower.  The collection of proteins was 
purified using the optimal conditions described in the Methods section. 
SDS-PAGE analysis of the purified test collection is shown in Fig. 3.  The TEV-cleaved 
HaloTag (~34 kDa) from HaloTag fusion proteins and HaloTEV protease (~80 kDa) were 
sometimes observed as weak contaminants.  It is not clear why both of these proteins were not 
removed by the Halo resin.  We confirmed that the eluted HaloTag contaminants were functional 
because they reacted with the SIFT ligand, but they were not selectively depleted from the 
elution fraction after re-binding eluate to fresh Halo resin.  The HaloTag band was more 
prominently observed with multiple proteins that are known to oligomerize when properly 
folded, such as WGE- and HCE-produced IKBKG, HADHSC, and p53.  Conceivably, the 
protein may have been captured through the HaloTag of one subunit of the oligomer, and the 
other members were captured by virtue of their oligomerization, leaving the HaloTag fusion of 
one or more of the subunits unbound to the resin and releasable by the TEV protease.  If this is 
the case, the abundance of cleaved HaloTag in the CF purifications and its absence in elution 
fractions of E. coli implies that proteins are better folded in the CF systems than in E. coli.  
However, this band was also observed with some proteins not expected to form homooligomers, 
such as HCE-produced BCL2A1, SNIP1, and GSK3B.  It is possible that some of these proteins 
may either stick to the resin non-specifically, or that aggregates may form around the POI and 
elute off when the POI is cleaved from the resin.  The presence of the HaloTag band and the 
absence of POI, seen predominantly with HCE-produced CCND1, SNIP1and CDKN2A, suggest 
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successful binding and cleavage of fusion protein, but failed release of the protein of interest 
from the resin. 
Using the HaloTag purification strategy, 14 of the 31 (45%) proteins in the collection had 
reasonable protein purification yield (1 µg) and high purity (>90%).  Of these 14, HCE was the 
most successful at making purified human protein with 13/31 (42%) successes.  Notably, the 
enrichment of protein purified from HCE is the greatest of the three systems, as HCE is by far 
the densest milieu of lysate proteins.  WGE and E. coli systems were less successful than HCE, 
with 10/30 (33%) and 6/30 (20%) proteins achieving these standards, respectively. 
Several POIs failed to purify, despite evidence of expression in at least two expression 
systems, such as CDKN2A, NIP7, CCND1, and MYC.  In some cases, the cause for failure was 
low purity.  To improve purity, several proteins were purified while testing more stringent wash 
conditions.  As wash stringency was increased to denaturing conditions, several proteins were 
found to stick more to the resin, suggesting that unfolded protein has higher non-specific affinity 
for the Halo resin.  Increasing wash stringency tended to lower purification yield, and therefore 
was not regarded as a suitable means to improve purity. 
To assess whether purified proteins were properly folded, several proteins within the test 
collection with known function were selected for functional analysis.  ABL1 is a non-receptor 
tyrosine kinases that autophosphorylates when it is functionally active
36
.    A kinase activity 
assay was performed with purified ABL1.  Figure 4 panel A shows that HaloTag-ABL1 was 
phosphorylated during expression in HCE, and subsequently dephosphorylated by phosphatase 
treatment while bound to Halo resin.  Following TEV cleavage and release, purified ABL1 auto-
phosphorylated in the presence of ATP.  Two other proteins in our test set, MAPK1 and p53, 
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have been shown formerly to interact
37
. To demonstrate that the purified proteins behave 
accordingly, a co-immunoprecipitation-like assay was performed.  MAPK1 was expressed in 
HCE as a c-terminal GST fusion protein, and following incubation of crude MAPK1-cGST with 
p53 purified from all three systems, the mixture was bound to glutathione resin.  Panel B shows 
that p53 purified from E. coli, WGE, and HCE all bound to MAPK1. 
 Table 1 summarizes the purification performance of the three expression systems.  
Among the successfully purified proteins, the mean recovery for the 3 systems was 42, 22, and 
15%, for E. coli, WGE, and HCE, respectively.  While HaloTag fusion protein specifically 
binding to Halo ligand on the magnetic resin was estimated to be highly efficient and consistent 
among the collection, the amount of POI that eluted was highly variable and protein dependent. 
Discussion 
A paramount obstacle for proteomic studies, such as the generation of affinity reagents to 
the human proteome, is the difficulty of high throughput recombinant protein production
6
.  This 
challenge is rooted in the need to accommodate many proteins with staggering biochemical 
diversity using a minimal set of protocols.  Functional proteomics, and in particular microarray 
based functional studies, can utilize purified protein at microgram scales.  A key goal of these 
applications is to have a very high protein production success rate, which contributes to lowering 
the cost of HT purification. 
We have attempted to establish a cost effective triage protocol to produce full-length 
proteins at high purity and a high success rate using in vivo E. coli expression, and two 
eukaryotic CF systems: WGE and HCE.  To this end, we compared the expression capabilities of 
three systems with 31 full-length human proteins.  CF expression systems had a much higher 
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success rate than E. coli, making them highly suitable for producing full-length eukaryotic 
proteins.  For the collection of proteins we assessed, 25/30 (83%) could be expressed in excess of 
20 μg in WGE and 26/31 (84%) in HCE.  In comparison, only 10/30 (33%) E. coli expressed 
proteins met these criteria, a subset that is biased towards smaller proteins in the collection.  
Among other rationales, slower translation rate in the presence of eukaryotic chaperones to 
support proper folding of complex eukaryotic proteins may contribute to high CF success 
rate
18,39
.  An advantage of the high expression rate of CF eukaryotic expression is a reduced need 
for a factorial approach involving many fusion tags, expression conditions, promoters, 
expression strains, etc, that are a part of many E. coli based production pipelines.  Adding these 
many constructs and protocols to a protein production pipeline greatly increases workload of 
protein production centers. 
The SIFT protocol we developed has several advantages over alternative protocols such 
as methods that couple immuno-precipitation with MCGE or automated CGE immunoblot 
methods for recombinant fusion protein analysis in complex biological samples.  Without the 
need for direct detection by antibodies or enrichment of non-specifically labeled protein, SIFT 
omits long incubation and washing steps.  The miniaturization of the microfluidic capillary 
channel in the chip reduces separation medium volume and separation time.  Each sample is 
processed in about 40 seconds, allowing the complete processing of a 96-well plate in about 90 
minutes.  In comparison, automated antibody-based CGE methods typically take upwards of 16 
hours to process a 96-well plate.  SIFT can provide qualitative and quantitative measurement of 
specific protein concentration that is on-par with in-gel fluorescence imaging.  A significant 
benefit to the SIFT approach is that it can be performed on existing LabChip systems with only 
minimal alteration of the sample preparation protocol.  SIFT can be easily extended to other 
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affinity tags that, like HaloTag, bind specifically and irreversibly to a fluorescently conjugated 
substrate, including SNAP and CLIP tags.   
There are alternative methods to label recombinant protein specifically, such as those that 
add fluorescent amino acid-charged tRNA, like FluoroTect GreenLys, into CF expression 
reactions
38
.  Although this method is a convenient approach to label all synthesized proteins, a 
relatively small fraction of proteins will be labeled and variable labelling can occur because there 
is a mixture of both natural aminoacyl-tRNA and the fluorescent variant in the expression 
reaction.  Furthermore, the number of fluorophores that different proteins incorporate will vary 
depending on the lysine composition of each protein.  An advantage of SIFT is that recombinant 
proteins are labeled through a highly efficient reaction with the fusion tag, and binding occurs 
with a stoichiometry of exactly one fluorophore per protein, allowing fluorescent signal to be 
correlated precisely with protein concentration. 
At the purification stage, 6/30 proteins were purified from E. coli, 10/30 purified from 
WGE, and 13/31 purified from HCE with yields ≥1 µg and ≥90% purity.  The average 
purification yield of E. coli was 5.8 μg, WGE 4.1 μg, and HCE 3.5 μg per reaction.  A number of 
proteins resulted in inefficient overall recovery.  One cause may be that the POI became 
insoluble after cleavage of the HaloTag fusion with TEV protease and, in turn, may cause some 
of these to bind non-specifically to the Halo resin.  Cleaved POI was observed on Halo resin by 
boiling the resin in SDS sample buffer after TEV cleavage and washing.  For these recalcitrant 
proteins, none of the conditions tested during optimization amended this problem. 
The HaloTag purification strategy achieved a combined 45% purification success rate 
with this diverse and challenging test collection.  Although we tested numerous parameters to 
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optimize the HaloTag purification protocol, the purification efficiency from these expression 
systems could be further improved, possibly with new Halo resin surface chemistry, or by using 
alternative affinity tags.  Functional assays revealed that purified proteins were active and 
therefore properly folded. 
One major limitation of CF systems is cost, which can be tens of times more expensive 
than in vivo E. coli protein expression.  Producing protein in cultured mammalian or insect cells 
remains both expensive and cumbersome, requiring long periods of cell growth, preparation of 
many cells, and laborious cell lysis methods that are not conducive to HT production.  The low 
success rate of prokaryotic systems, and the low throughput and high cost of in vivo eukaryotic 
protein expression, make eukaryotic CF systems attractive choices for HT protein production for 
proteomic studies.  Ongoing technical developments in structural biology are reducing the 
amount of material needed for protein structure determination
40,41
, and may lead to increased CF 
system usage within structural biology
19,27
. 
CF systems are capable of producing the amount of protein required by proteomic 
applications, such as emergent affinity reagent development pipelines.  For applications that 
require quantities of protein near the 100 μg protein scale, a range that is generally considered 
necessary for current affinity reagent selection and characterization techniques, CF expression 
volumes can be increased as needed.  When doing this, the overall cost of producing protein 
increases with CF expression volume.  However, some proteins cannot be produced using E. 
coli, and there may be no low-cost and HT alternatives for these targets.  As with any production 
pipeline, throughput decreases substantially when working with volumes that exceed the capacity 
of a deep well block format, although in some cases it may be reasonable to use multiple deep 
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well blocks in parallel and combine the relevant wells.  Otherwise, highly specialized equipment 
is required in order to maintain throughput of larger scale work. 
Based on these results, our proposed full-length human protein production triage strategy 
is shown in Fig. 5.  The order is dependent on the application and required scale.  For larger 
quantities of protein, E. coli is well worth screening first for expression and purification, to find 
proteins that can be produced cheaply before moving onto the more costly CF systems.  
However, for applications that can utilize smaller amounts of protein, CF systems’ high success 
rate makes them a good first choice.  Our automated pipeline, including SIFT, enables efficient 
assessment of this triage strategy for a large number of proteins.  Proteome-level protein 
production remains an unsolved challenge.  We have reported that the incorporation of CF 
expression into a high throughput pipeline can expand the scope of proteins that can be produced 
and isolated for proteomic research.  Our ultimate goal is to further improve our pipeline to 
eventually support proteome-level full-length protein production for various proteomics 
applications. 
Materials and Methods. 
Cloning.  Three Gateway compatible destination vectors were cloned as illustrated in Fig. S1.  
The HaloTag7 and Tobacco Etch Virus (TEV) protease cleavage site linker encoding sequence 
was amplified from pFN22A (Promega) with a 5’ NdeI site and 3’ BsrGI site, and ligated into 
pCPD_nMBP (DNASU.org) linearized by NdeI and BsrGI, to generate pCPD_nHalo_empty 
(Fig. S1).  The Gateway death cassette was amplified from a modified pANT7_cGST destination 
vector with 5’ and 3’ BsrGI sites, and ligated into pCPD_nHalo_empty linearized by BsrGI, to 
generate pCPD_nHalo_DC, the Gateway compatible destination vector for E. coli expression.  
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To create pJSP6_nHalo_empty, the HaloTag sequence was amplified with 5’ NcoI and 3’ PmeI 
sites, and ligated into NcoI and PmeI linearized pEU_HSBC.  WGE destination vector 
pJSP6_nHalo_DC was generated by ligating the death cassette, amplified with 5’ and 3’ SgfI and 
PmeI restriction sites, into SgfI and PmeI linearized pJSP6_nHalo_empty.  To generate 
pJFT7_nHalo_empty, the HaloTag sequence was amplified from pCPD_nHalo with a 5’ NcoI 
site, and a 3’ SpeI site, and ligated into a modified version of pANT7_cGST with an NcoI site 
introduced immediately after the EMCV IRES, which was linearized with NcoI and SpeI.  The 
death cassette with 5’ and 3’ BsrGI sites was ligated into BsrGI linearized pJFT7_nHalo_empty 
to generate pJFT7_nHalo_DC for HCE expression.  Maps and sequences of these vectors can be 
found at http://dnasu.org/.  The cDNA for the test collection was acquired from DNASU and 
transferred into the three destination vectors via LR cloning (Fig. S1).  All constructs were 
sequenced verified.  CF expression plasmids were prepared using NucleoBond Xtra midi or 
maxi-prep kits (Macherey Nagel). 
E. coli in vivo expression.  Expression plasmids were transformed into E. coli strain Rosetta2 
(DE3) (EMD Millipore) and cultured in a 96-well format as previously described 
9
.  The 
expression protocol was adapted from a previously described protocol 
16
.  Briefly, Isolated 
colonies were grown in 1 mL LB media + 100 µg/mL Ampicilin, 34 µg/mL Chloramphenicol, 
0.4% glucose, in a 96 well, 2 mL deepwell block (R.K. Manufacturing), overnight at 37 °C.  The 
cultures were diluted 1:20 into 2 mL supplemented MJ9 media and grown in 24-well, 10 mL 
deepwell blocks (Seahorse Bioscience), for ~2.5 h at 37 °C until OD600 = 0.5-0.6.  Cultures were 
cooled to 18 °C for 15 min, and expression was induced with 1 mM IPTG.  After 18 h, 
expression cultures were pelleted at 6,000 x g for 10 min, and resuspended in 250 μL lysis buffer 
(50 mM HEPES, 150 mM NaCl, pH 7.8, 0.01% IGEPAL, 1 mM DTT, 2 mg/mL lysozyme, 25 
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µg/mL DNase, 5 mM Mg
2+
, 100 µM PMSF).  Lysates were kept frozen at -20 °C and re-thawed 
for purification. 
CF expression.  WGE expression was performed with WEPRO7240 (CellFree Sciences) in a 
226 μL bilayer format using flat-bottom 96 well plates (Greiner) following the manufacturer’s 
protocol, for 20 h at 15 °C.  For HCE expression, reaction mix was prepared according to the 
manufacturer’s instructions (Thermo-Pierce).  The reaction mixture was centrifuged at 10,000 x 
g for 2 min, and 105.6 μL of supernatant was aliquoted per reaction into a 96-well PCR plate.  
For each reaction, 4.4 μL of 1 μg/μL expression plasmid was mixed with the clarified IVTT 
mixture, and 100 μL of the IVTT reaction was transferred into a dialysis chamber of a 96-well 
microdialysis plate (Thermo-Pierce).  The dialysis chambers were equilibrated with 20 min 
soaking in 1.8 mL, 30 °C, 1X dialysis buffer (Thermo-Pierce) prior to adding the IVT reaction.  
Following 20 h, 30 °C expression, lysates were transferred to a 96-well PCR plate, and 
centrifuged for 6,000 x g for 10 min. 
HaloTag Alexa660 Ligand synthesis.  One milligram (1 mg) NHS-activated Alexa660 (Life 
Technologies) was incubated with 0.6 mg HaloTag amine ligand (Promega) in anhydrous DMF 
containing 50 mM DIPEA (diisopropylethyl amine) at 37 °C overnight, purified by reverse phase 
HPLC on a C18 column with a 0-96% MeOH in water, 2% per min gradient, and characterized 
by monitoring the absorbance at 660 nm. 
SDS-PAGE expression analysis and HaloTag-specific detection.  E. coli, WGE, and HCE 
expression reactions were diluted in 1X HEPES (50 mM HEPES, 150 mM NaCl, pH 7.8) 1:10, 
2:5, and 1:5, respectively, to normalize the concentration of HaloTag protein.  Samples were split 
into supernatant and total fraction plates.  Supernatant plates were centrifuged 5,000 x g for 20 
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min, and the supernatants were transferred into new plates.  These samples were analyzed with 
SDS-PAGE by incubating fractions of lysate with 4 µM Alexa660-conjugateded Halo ligand 
(Promega) for 20 min at room temperature, and denaturating in Laemmli sample buffer with 
boiling at 85 °C for 3 min.  The ratio of diluted sample to 4 µM Alexa660-HL to 4X Laemmli 
sample buffer (Bio-Rad) was 2:1:1, making the final E. coli, WGE, and HCE dilutions 1:20, 1:5, 
and 1:10, respectively.  Gels were loaded with 10 μL of sample and run until separation was 
satisfactory.  Gels were imaged using a Typhoon fluorescent imager (GE Life Sciences).  Gels 
were subsequently stained with Simply Blue Coomassie stain (Life Technologies).  Gels images 
were analyzed using ImageQuantTL software (GE Life Sciences).  A HaloTag protein standard 
was used to create a molar calibration curve.  Molarity was converted to protein mass using the 
theoretical mass of each fusion protein. 
LabChip HaloTag-specific expression analysis.  Lysed E. coli, WGE, and HCE samples, 
arrayed in 96-well PCR plates, were diluted 1:10, 2:5, and 1:5 in 50 mM HEPES, 150 mM NaCl, 
pH 7.8.  The plates were centrifuged 5,000 x g for 20 min, and the supernatants were transferred 
to new plates.  These samples were diluted 2:3 with 4 µM Alexa660-HaloTag ligand, and 
incubated for 20 min at room temperature.  Sample plates were frozen at -80 °C for storage and 
transportation.  Samples were thawed, and 2 μL of sample was added to 17 μL of denaturating 
Pico Protein Sample buffer containing DTT, and prepared according to the manufacturer’s 
instructions.  Samples were centrifuged at 2,000 x g for 2 min, denatured at 95 °C for 5 min, and 
35 μL of MilliQ water was added to each sample.  Samples were centrifuged at 2,000 x g for 2 
min, and the sample plates were run sequentially on a LabChip GXII instrument using the Pico 
Protein 200 assay.  The Pico Protein ladder was prepared in Pico Labeling Buffer, and a HT 
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Protein chip was prepared, both according to the manufacturer’s instructions.  Electropherograms 
and virtual gels were analyzed using LabChip GX software. 
HaloTag purification.  Magne HaloTag resin (Promega) was equilibrated with HaloTag 
purification buffer (HPB): 50 mM HEPES, 150 mM NaCl, pH 7.8, 1 mM DTT, 0.01% IGEPAL, 
supplemented with 2 mM ATP and 10 mM MgSO4.  Lysed E. coli, WGE, and HCE reactions 
were clarified at 5,000 x g for 20 min prior to binding to equilibrated resin.  For each sample, 
382 μL equilibrated-resin slurry, which contained 10 μL of settled resin, was aliquoted into a 2 
mL deepwell block.  Protein was bound for 2 h with vigorous shaking at 1,000 rpm at room 
temperature.  Resin was washed five times with 500 μL of HPB, with 5 minute 1,000 rpm 
shaking intervals, using a Biomek FX liquid handling robot (Beckman Coulter).  Protease 
cleavage was performed by adding 100 μL of 30 ng/μL HaloTEV protease (Promega), diluted in 
HPB, to each sample, and shaking for 2 h at room temperature.  The 100 μL of elution fraction 
was collected and analyzed by SDS-PAGE. 
SDS-PAGE purification analysis.  Elution fractions were collected and diluted in 2X Laemmli 
sample buffer (Bio-Rad), boiled for 3 min at 85 °C, and separated on Criterion 4-20% TGX gels 
(Bio-Rad).  Coomassie stained gels were image quantified using BSA protein standard (Thermo). 
ABL1 kinase assay.  Following expression in HCE, 2 µL of ABL1-nHalo in HCE lysate was 
bound on 2.5 µL of HaloTag resin equilibrated and suspended in 100 µL HPB, at room 
temperature for 1 h with shaking.  Resin was washed 5X with 100 µL HPB with 5 min shaking 
intervals between washes.  The resin was suspended in 100 µL of HPB and was split into three 
30 µL aliquots.  One of the aliquots was left in HPB, and the other two were incubated in 30 µL 
PPase reaction buffer [10% λ-PPase, 50 mM HEPES, 10 mM NaCl, 2 mM DTT, 0.01% Brij 35, 
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pH 7.5, 1 mM MnCl2 (NEB)] added.  The PPase reaction was performed at 30 °C with shaking 
for 1 h.  Resin was washed 5X with 100 µL HPB with 5 min shaking intervals between washes.  
All fractions were cleaved with 30 µL 30 ng/µL TEV protease in HPB at room temperature for 1 
h with shaking.  One of the PPase treated fractions was incubated with 30 µL kinase buffer [25 
mM Tris, pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4, 10 mM MgCl2, 0.5 
mM ATP (Cell Signaling)], at 30 °C with shaking for 1 h.  All aliquots of resin were boiled for 5 
min at 85 °C in Laemmli sample buffer and 10 µL was loaded and run on an SDS-PAGE gel, 
transferred to a PVDF membrane, and blotted with anti-Abl1 or anti-pY (Cell Signaling). 
MAPK1 and p53 protein-protein interaction assay.  MAPK1 was expressed in HCE using the 
pANT7_cGST as the expression vector.  A 20 µL aliquot of MAPK1-cGST expressed in HCE 
was mixed with 0.5 µg of purified p53 from E. coli, WGE, and HCE, with the volume finalized 
to 85 µL with PPI buffer (PBS, 0.05% TritonX-100, 5 mM MgCl2, 10 mg/mL BSA, 0.5 mM 
DTT).  For no-bait controls, 20 µL of PPI buffer was substituted for MAPK1-cGST.  The 
mixtures were incubated for 2 h at 4 °C and bound to 25 µL PPI equilibrated 50% glutathione 
resin slurry, overnight at 4 °C with rotating.  The resin was washed 7X with 500 µL PPI buffer.  
The resin was suspended in a final volume of 75 µL Laemmli sample buffer and boiled for 10 
min at 85 °C.  Immunoblotting was performed on 10 µL loaded sample with anti-p53 D01 (Santa 
Cruz). 
Electronic Supplementary Material.  Figures S1-S4, and Table S1 are contained within 
FLHPP-Supporting-Information.docx.  Figure S1 illustrates the design of the three HaloTag 
expression vectors.  Table S1 provides information on the human protein test collection.  Figure 
S2 illustrates the format of the three expression systems.  Figure S3 compares slab gel 
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coomassie, HaloTag in-gel fluorescence, and HaloTag MCGE signal for the test collection.  
Figure S4 plots LabChip and in-gel HaloTag fluorescence quantification. 
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Figures Legends 
Figure 1.  Comparison of slab gel and LabChip expression analysis of AKT3 and MAPK, which were 
expressed in HeLa cell extract (HCE).   Total protein signal can be observed by staining the slab gel with 
Coomassie, while recombinant HaloTag signal can be detected with in-gel fluorescence.  For high 
throughput analysis, the LabChip system can be utilized for measuring total protein content using the 
Pico Protein Express protocol, whereas HaloTag signal can be distinguished with selective irreversible 
fluorescent targeting (SIFT). 
Figure 2.  SIFT expression analysis of HaloTag fusion proteins.  (A)Virtual gel images of the full-length 
human protein collection expressed as N-terminal HaloTag fusion proteins in E. coli, wheat germ extract 
(WGE), and HeLa cell extract (HCE) systems.  Following expression, supernatant fractions of reactions 
were diluted 1:20, 1:5, and 1:10 for E. coli, WGE, and HCE, respectively, incubated with the SIFT Ligand, 
and analyzed using a LabChip GX instrument.  Arrows point to the protein of interest.  (B) The heat map 
displays yield per reaction.  Proteins that were not determined are shaded black. 
Figure 3.  Purification analysis of 31 full-length proteins in E. coli, wheat germ extract (WGE), and HeLa 
cell extract (HCE) systems.  (A) Coomassie stain of 5/100 µL elution fraction.  Red arrows indicate 
sufficient yield (>1 μg) and high (>90%) purity, while black arrows indicate low yield and/or purity.  
Proteins that were not determined are shaded black.  (B) Heat map showing quantification of yield and 
purity of elution fractions.  Note: the GSKIP construct that was used contains a second TEV site 
immediately upstream of gene start codon, and the smaller band seen in these elution fractions 
corresponds to the twice TEV cleaved product. 
Figure 4.  Functional assays of selected purified proteins.  (A) Auto-phosphorylation of purified, de-
phosphorylated ABL1.  ABL1 kinase was prepared by expression in HCE as an N-terminal HaloTag fusion 
protein, binding to resin, dephosphorylation and cleavage from the resin with TEV protease.  Purified 
protein was then incubated with and without ATP.  Phosphotyrosine signal was detected by 
immunoblotting with anti-phosphotyrosine.  (B) Interaction of purified p53 with MAPK1.  The MAPK1-
p53 interaction was queried by incubating HCE-produced MAPK1-cGST with p53 purified from E. coli, 
WGE, and HCE.  The MAPK1-cGST and p53 mixtures were bound onto glutathione resin, washed, and 
boiled in SDS-PAGE sample buffer.  Glutathione resin was incubated with p53 alone as a negative 
control.  Immunoblotting was performed to detect p53 signal. 
Figure 5.  Decision tree of full-length human protein purification in E. coli, WGE, and HeLa lysate systems 
for larger scale applications. 
